MARKET

DNA

DNA

Ginkgo Bioworks Holdings Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

5.79
-0.35
-5.70%
After Hours: 5.85 +0.06 +1.04% 19:59 01/14 EST
OPEN
6.11
PREV CLOSE
6.14
HIGH
6.42
LOW
5.63
VOLUME
13.33M
TURNOVER
--
52 WEEK HIGH
15.86
52 WEEK LOW
5.63
MARKET CAP
9.68B
P/E (TTM)
0.0000
1D
5D
1M
3M
1Y
5Y
Piscataqua Savings Bank Buys Materials Select Sector SPDR, Vanguard S&P 500 ETF, Waste ...
Investment company Piscataqua Savings Bank (Current Portfolio) buys Materials Select Sector SPDR, Vanguard S&P 500 ETF, Waste Management Inc, iShares Core S&P Small-Cap ETF, iShares Core S&P Mid-Cap ETF, sells LyondellBasell Industries NV, DuPont de Nemour...
GuruFocus.com · 2d ago
Why Ginkgo Bioworks Shares Are Trading Higher Today
Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher Wednesday after the company reported preliminary unaudited 2021 revenue highlights and a business review.
Benzinga · 4d ago
BNGO, DIDI and RKLB among pre market gainers
Immuron IMRN +63% after receiving A$6.2M award from U.S. DoD for Travelan. Immix Biopharma (NASDAQ:IMMX) +34% IMX-110 produced 50% positive response rate in first-line-therapy-resistant cancer, surpassing the standard of care in mice study.
Seekingalpha · 4d ago
Ginkgo Bioworks rises 5% on positive 2021 revenue expectations
Ginkgo Bioworks (NYSE:DNA) expects to meet or exceed its key 2021 full year targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings, as
Seekingalpha · 4d ago
Ginkgo Bioworks Says Prelim. Unaudited Foundry Revenue Expected To Exceed $100M For FY21, Biosecurity Revenue Expected To Exceed $110M
Expects to meet or exceed 2021 performance targets for new cell programs, Foundry revenue, and Biosecurity revenue Management to highlight updates today at the 40th Annual J.P. Morgan Healthcare Conference at 3:45pm
Benzinga · 4d ago
BRIEF-Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights And Business Review
reuters.com · 4d ago
Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December 31, 2021. Among the results, Ginkgo highlighted that it expects to meet or exceed its key 2021 fu...
PR Newswire · 4d ago
Selecta taps Ginkgo for deal worth up to $1.1B
Selecta Biosciences Inc. has chosen Ginkgo Bioworks Holdings Inc. to develop new viral capsids for gene therapies.
American City Business Journals · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DNA. Analyze the recent business situations of Ginkgo Bioworks Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DNA stock price target is 13.88 with a high estimate of 15.00 and a low estimate of 12.00.
High15.00
Average13.88
Low12.00
Current 5.79
EPS
Actual
Estimate
-0.39-0.29-0.18-0.07
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 127
Institutional Holdings: 754.57M
% Owned: 45.11%
Shares Outstanding: 1.67B
TypeInstitutionsShares
Increased
16
92.19M
New
82
651.77M
Decreased
21
15.84M
Sold Out
98
63.84M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About DNA
Ginkgo Bioworks Holdings, Inc., formerly Spinning Eagle Acquisition Corp, is engaged in building a platform to program cells. The Company's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products as therapeutics, key food ingredients, and chemicals derived from petroleum. The Company's platform is used to design, write, and debug deoxyribonucleic acid (DNA) code in engineered organisms to execute programs for its customers. Its platform is used by customers for manufacturing processes or develop new products through biology. The foundation of its platform includes two assets that execute a variety of cell programs for customers according to their specifications: Foundry and Codebase. It serves industries, including chemicals, agriculture, food, consumer products and pharmaceuticals.

Webull offers kinds of Ginkgo Bioworks Holdings Inc stock information, including NYSE:DNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DNA stock methods without spending real money on the virtual paper trading platform.